New York, New York (NetworkNewsWire) – NetworkNewsWire Editorial
Coverage: As the marijuana market continues its widespread growth,
researchers remain merely at the threshold of exploring the
manifold potential medical applications of cannabis. At present,
more than 90 individual cannabinoid compounds have been discovered
within the cannabis plant—each one potentially possessing crucial
disease-fighting properties either on its own or combined with
other compounds. Historically, however, it has been incredibly
difficult to extract most of these compounds from the marijuana
plant in adequate quantities and purities to be tested
pharmaceutically. Overcoming this stumbling block in medical
cannabis advancement, Vancouver-based biopharmaceutical company
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
(IMLFF
Profile) has developed a pioneering,
high-yield biosynthesis process that enables the manufacture of all
90+ naturally occurring cannabinoids. This groundbreaking
development could have an enormous impact in forwarding the efforts
of other companies within the cannabis sector, including GW
Pharmaceuticals (NASDAQ: GWPH), Zynerba
Pharmaceuticals, Inc. (NASDAQ: ZYNE),
Axim Biotechnologies, Inc. (OTCQB: AXIM) and
22nd Century Group, Inc. (NYSE: XXII).
InMed
Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) novel
approach to cannabinoid biosynthesis represents a potentially
game-changing breakthrough in drug development. Many efforts by
other companies to develop synthetic cannabis derivatives have
failed. In comparison with other microbial platforms, InMed’s E.
coli system has proven, through substantial experimentation, to be
heartier and more efficient for the manufacturing of
cannabinoids.
The process of naturally sourcing most cannabinoid compounds
from the cannabis plant is extremely time-consuming, involving the
tasks of planting, growing, harvesting and extracting. It is also
very costly; can be low-yielding because of crop fluctuations; and
involves various hard-to-remove impurities like pesticides,
herbicides and fertilizers. Additionally, this process yields only
two to three cannabinoids that can reach adequate quantities to
justify the process; the remaining cannabinoid compounds are only
yielded in trace amounts and are not accessible through natural
sources.
While many have tried to chemically synthesize these compounds
for pharmaceutical use, the chief problem with such an approach is
it is usually very hard to derive cannabis compounds that are
identical to the ones that occur naturally. Slight variations in
structure can change both the effectiveness and safety of these
compounds. The difficulty, tedium, costliness and time-consuming
nature of the process is, overall, off-putting and creates a great
deal of chemical waste.
The proprietary cannabinoid manufacturing process pioneered by
InMed addresses this problem through biosynthesis, which is the
process of utilizing naturally occurring cannabinoid DNA to produce
cannabinoid compounds in a laboratory setting. The advantages of
this process are multifold, resulting in:
- Compounds that are identical to naturally occurring
cannabinoids
- Pure, individual cannabinoids that can be manufactured without
the necessity of separating the many compounds from one
another
- A time- and cost-effective process
- High quality control throughout the process thanks to
production in a laboratory setting
- The capability for all 90+ cannabinoids to be manufactured for
the same reasonable cost
InMed is thus able to tap into the enormous medical potential of
every cannabinoid, in particular the minor ones, due to this
ability to access them in an economically sound way. The financial
and time-consuming nature of other biosynthesis methods continue to
pose stumbling blocks for other pharmaceutical companies.
Recently, InMed announced the filing of a provisional patent
application—the first of many—relating to this proprietary
biosynthesis program for manufacturing cannabinoids (http://nnw.fm/Z30dH). Once converted into an
international Patent Cooperation Treaty (PCT) application and
pursued in key jurisdictions on a global scale, this first patent
application will give InMed significant commercial protection for
its biosynthesis program, which is an E. coli-based expression
system. This series of patent applications will particularly focus
on the superiority of E. coli-based expression systems in
comparison to other approaches; maximizing production of
cannabinoids and related compounds through gene optimization; and
additional proprietary developments and data related to InMed’s
breakthrough biosynthesis program. Over time, InMed intends to
actively convert this first patent filing, along with subsequent
provisional patents, into national-stage filings in every major
commercial jurisdiction.
InMed’s revolutionary cannabinoid biosynthesis program is one of
three core assets for the company. The other two are a
bioinformatics assessment tool that targets specific cannabinoids
in treating key diseases and a drug development program that
includes INM-750 for Epidermolysis bullosa and INM-085 for
glaucoma.
InMed is assembling a strong management team to bring its
biosynthesis program to commercialization. This team includes Ben
Paterson, P.E., whose consulting services were recently retained by
InMed (http://nnw.fm/vx1Bo). Paterson previously served as a
senior engineering advisor for Eli Lilly and Company, spending 24
years in that company’s biosynthesis division. His extensive
expertise will help InMed transition from pilot-scale to
commercial-scale manufacturing.
The company’s management team also includes president and CEO
Eric A. Adams, who is a veteran biopharmaceutical executive with
extensive experience in company and capital formation, global
market development, mergers and acquisitions, and licensing and
corporate governance; Chief Scientific Officer Dr. Sazzad Hossain,
Ph.D., M.Sc., who has more than two decades of academic and
industrial experience in new drug discovery and natural health
product development; Chief Medical Officer Dr. Ado Muhammed, MD,
DPM, MFPM, who is a proven leader in developing cannabinoid
therapies; Alexandra D.J. Mancini, M.Sc., who serves as the senior
vice president of clinical and regulatory affairs and possesses
more than 30 years of global biopharmaceutical R&D experience,
with emphasis in clinical development and regulatory affairs; and
CFO Jeff Charpentier, who is a biopharmaceutical industry veteran
with more than 25 years of experience.
InMed’s breakthrough approach to cannabinoid biosynthesis has
enormous potential in helping other companies in their
cannabis-related drug development efforts—companies like GW
Pharmaceuticals (GWPH), the company behind the world’s
first prescription drug derived from the cannabis plant, Sativex®,
which is approved for the treatment of spasticity due to multiple
sclerosis. GWPH’s lead cannabinoid product candidate is Epidiolex®,
a liquid formulation of pure plant-derived cannabidiol being
developed for the treatment of a number of rare childhood-onset
epilepsy disorders. Other companies include Zynerba
Pharmaceuticals (ZYNE), whose product
candidates are “synthetically manufactured per FDA/CGMP
regulations” in an effort to “provide consistent potency and
eliminate impurities in the product”; Axim Biotechnologies
(AXIM), which is developing a clinical pipeline of
cannabinoid-based products such as its MedChewRx™ chewing gum for
the treatment of irritable bowel syndrome; and 22nd Century
Group (XXII), a plant biotechnology company focused on
genetic engineering and plant breeding which allows the increase or
decrease of the level of nicotine in tobacco plants and the level
of cannabinoids in cannabis plants. The availability of all 90+
cannabinoid compounds enabled by InMed’s process could mean the
difference between success and failure in the development of drugs
to treat various key diseases.
"This novel approach to the biosynthesis of cannabinoids is a
game-changer for drug development,” said Dr. Vikramaditya Yadav,
assistant professor of Chemical and Biological Engineering at the
University of British Columbia and a co-inventor of InMed’s
biosynthesis technology (http://nnw.fm/Z30dH). “The importance of producing
cannabinoids that are identical to the naturally occurring
compounds cannot be overstated. Many drug development efforts with
synthetic derivatives have failed.”
With roadways opening up in cannabinoid research and this
pioneering new access to every cannabinoid compound rather than
just a few of them, the potential is virtually limitless as
companies like those named pursue drug development activities
within the medical cannabis field. There is no telling what
breakthrough cures and treatments may emerge as a result, but it is
indeed an exciting time in the burgeoning cannabis space.
For more information on InMed Pharmaceuticals, please visit:
InMed
Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
22nd Century (AMEX:XXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Sep 2023 to Sep 2024